Mizuho Medy Co., Ltd. AI Stock Analysis
Want to see JP:4595 full AI Analyst Report?
Mizuho Medy Co., Ltd. (4595) AI Stock Analysis
Mizuho Medy Co., Ltd.
(TSE/TYO:4595)
The score is driven primarily by solid fundamentals: a debt-free balance sheet, high equity ratio and above-average margins, tempered by a meaningful revenue contraction from pandemic-era highs, margin compression and weaker cash conversion. Valuation is a clear positive, with a single-digit P/E and a near 6% dividend yield backed by positive free cash flow. The main drag is technical weakness, as the stock trades below all key moving averages with negative MACD and subdued RSI/stochastic readings, suggesting limited near-term momentum despite the attractive fundamental and valuation profile.
Mizuho Medy Co., Ltd. (4595) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 32.12B
- Dividend Yield
- 5.93%
- Average Volume (3M)
- 77.42K
- Price to Earnings (P/E)
- 9.4
- Beta (1Y)
- 0.40
- Revenue Growth
- 16.55%
- EPS Growth
- 21.38%
- Country
- Japan
- Employees
- 193
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Mizuho Medy Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While i...
How the Company Makes Money
The company primarily makes money by selling IVD products, with revenue largely driven by diagnostic reagents and test kits that are consumed repeatedly as tests are performed. A typical revenue model in this business consists of (1) recurring consum...
Mizuho Medy Co., Ltd. Financial Statement Overview
Summary
Mizuho Medy combines a pristine balance sheet (zero debt, ~84% equity ratio, equity grown from ¥3.8B in 2020 to ¥18.7B) with still-strong profitability (30.4% net margin, 43.6% EBITDA margin) and modest 4.9% revenue growth. Offsetting this, revenue has fallen sharply from the 2022 peak of ¥17.6B to ¥11.3B, gross margins compressed from 80.2% to 69.1%, and cash conversion has weakened (operating cash flow down to ¥2.0B from ¥3.3B, OCF/net income of 0.74). Overall a financially sound business normalizing after pandemic-driven demand.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.82B | 11.26B | 11.43B | 10.99B | 17.58B | 12.89B |
| Gross Profit | 7.40B | 7.78B | 8.04B | 8.03B | 14.05B | 9.61B |
| EBITDA | 4.44B | 4.91B | 5.10B | 5.40B | 11.26B | 6.87B |
| Net Income | 3.23B | 3.42B | 3.77B | 3.77B | 7.84B | 4.82B |
Balance Sheet | ||||||
| Total Assets | 20.99B | 22.38B | 20.73B | 18.95B | 19.10B | 12.19B |
| Cash, Cash Equivalents and Short-Term Investments | 13.06B | 10.82B | 11.25B | 10.13B | 8.70B | 4.33B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.43B | 3.69B | 3.37B | 3.27B | 4.82B | 4.16B |
| Stockholders Equity | 18.55B | 18.68B | 17.35B | 15.68B | 14.28B | 8.03B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.70B | 3.05B | 3.73B | 5.99B | 5.44B |
| Operating Cash Flow | 0 | 1.96B | 3.35B | 3.99B | 6.17B | 5.60B |
| Investing Cash Flow | 0 | -7.28B | -307.00M | -270.45M | -1.55B | -159.74M |
| Financing Cash Flow | 0 | -2.08B | -2.09B | -2.38B | -1.57B | -1.16B |
Mizuho Medy Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Negative. The current price of 1686.00 is below the 20-day moving average (MA) of 1708.35, below the 50-day MA of 1715.44, and below the 200-day MA of 1715.22, indicating a bearish trend. The MACD of -3.64 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 22.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4595.
Mizuho Medy Co., Ltd. Peers Comparison
Overall Rating
JP:459573Outperform
JP:453473Outperform
JP:455469Neutral
JP:488669Neutral
JP:453946Neutral
JP:489242Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | JPY 32.39B | 9.41 | ― | 5.93% | 16.55% | 21.38% | |
| 73Outperform | JPY 114.51B | 11.06 | 7.68% | 2.45% | 15.85% | 60.55% | |
| 69Neutral | JPY 46.15B | 15.58 | 5.56% | 3.03% | 20.72% | -10.35% | |
| 69Neutral | JPY 56.74B | 11.31 | ― | 3.14% | ― | 9.04% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | JPY 5.70B | -11.69 | ― | 3.25% | 0.31% | -194.72% | |
| 42Neutral | JPY 5.08B | -6.33 | ― | ― | 214.65% | 22.18% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4595 | Mizuho Medy Co., Ltd. | 1686.00 | 158.69 | 10.39% | |
| JP:4554 | Fuji Pharma Co., Ltd. | 1717.00 | -0.78 | -0.05% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3365.00 | 84.75 | 2.58% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1540.00 | 59.18 | 4.00% | |
| JP:4886 | ASKA Pharmaceutical Holdings Co., Ltd. | 2072.00 | 67.40 | 3.36% | |
| JP:4892 | Cyfuse Biomedical K.K. | 487.00 | -83.00 | -14.56% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
